The Trump Administration Is Shifting Federal Policy On Cannabis And Psychedelics |
In this week’s edition of InnovationRx, we look at the Trump administration’s moves on medical marijuana and psychedelics, a new partnership, a brain implant deal, and more. To get it in your inbox, subscribe here.
Last week, the Trump administration reclassified marijuana from a Schedule I to a Schedule III drug in states that have licensed it for medical purposes. Acting Attorney General Todd Blanche said that the Justice Department will hold a hearing in June about reclassifying marijuana generally as a Schedule III drug, treating it more like anabolic steroids than heroin.
The move follows a December executive order from the president directing then-Attorney General Pam Bondi to complete the rulemaking process for this change, which had begun under the Biden administration. It also comes on the heels of an executive order to accelerate research and access to psychedelic drugs for the treatment of mental illness.
The actions don’t legalize these drugs, though they do potentially reduce penalties and enforcement priorities for any violation of federal........